Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 9/20 | 0.38 |
| ▸ | TK2 | O00142 | 7/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135171 | 1.00 | TK1 (0.38) | TK1TK2HPGD | |
| SCHEMBL4856132 | 0.90 | HSP90AA1 (0.38) | TK1 | |
| SCHEMBL4592382 | 0.89 | TK2 (0.36) | TK1TK2HPGD | |
| SCHEMBL1727535 | 0.88 | RNASE1 (0.40) | TK1TK2 | |
| SCHEMBL7743997 | 0.88 | TK1 (0.37) | TK1TK2 | |
| SCHEMBL2379938 | 0.87 | RNASE1 (0.37) | TK1TK2 | |
| SCHEMBL8426742 | 0.86 | TK1 (0.38) | TK1TK2 | |
| SCHEMBL8370048 | 0.85 | RNASE1 (0.38) | TK1TK2 | |
| SCHEMBL29834197 | 0.84 | TK1 (0.36) | TK1TK2 | |
| SCHEMBL7863893 | 0.83 | RNASE1 (0.37) | TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113020-B1 | Nucleosides and oligonucleotides containing boron clusters | UNIV EMORY (US) | 2009-10-28 | — | — | EP | disclosed |
| US-6583122-B2 | Use in boron neutron capture therapy (BNCT) and diagnostic purposes; treating cancer, viral infections such as HIV, hepatitis B virus | EMORY UNIVERSITY | 2003-06-24 | — | — | US | disclosed |
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | DEPARTMENT OF VETERANS AFFAIRS | 2002-10-31 | — | — | US | disclosed |
| EP-1113020-A2 | Nucleosides and oligonucleotides containing boron clusters | EMORY UNIVERSITY (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6180766-B1 | OLIGONUCLEOTIDE WITH UNCHARGED INTERNUCLEOTIDE LINKAGE(S) OF 3',5'-O,O-((CARBORAN-1-YL-METHYL)PHOSPHONATE); MADE BY REACTING O-METHYL(O-CARBORAN-1-YL)METHYL PHOSPHONATE WITH PROTECTED NUCLEOSIDE; USE IN BORON NEUTRON CAPTURE THERAPY | DEPARTMENT OF VETERANS AFFAIRS | 2001-01-30 | — | — | US | disclosed |
| US-5872107-A | ANTICARCINOGENIC AGENTS CAPTURE THERAPY FOR TUMORS | EMORY UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0731808-A4 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5599796-A | USING BORON CLUSTER-CONTAINING NUCLEOSIDES OR OLIGONUCLEOTIDES; PARTICULARLY EFFECTIVE FOR BLADDER, PROSTATE AND KIDNEY | EMORY UNIVERSITY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0731808-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015333-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
| US-4469863-A | ANTITUMOR AGENTS, VIRICIDES | GENTA INCORPORATED | 1984-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | NUDT1, NTPCR, NAMPT | TK1 76/4885TK2 93/4885HPGD 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.